List view / Grid view
A novel PPAR alpha/delta agonist “could provide an important new…
A novel PPAR alpha/delta agonist “could provide an important new therapeutic option for long-term treatment [of primary biliary cholangitis (PBC)].
Onivyde® (irinotecan liposome injection) treatment regimen significantly improved survival in…
Onivyde® (irinotecan liposome injection) treatment regimen significantly improved survival in a Phase III trial compared to nab-paclitaxel plus gemcitabine.
The combination was approved on Phase III trial results which…
The combination was approved on Phase III trial results which show it doubled progression-free survival and reduced risk of death by 40 percent, compared to standard of care.
